French biotech Abivax's shares soared amid positive Phase 3 results for its experimental miRNA-124 enhancer, obefazimod, in treating moderately to severely active ulcerative colitis. Two pivotal trials demonstrated a 16.4% placebo-adjusted clinical remission rate at eight weeks with favorable safety profiles, outperforming prior phase 2 data. Abivax is conducting a 44-week maintenance study with top-line data expected next year and plans regulatory submissions in the latter half of 2026. Analysts project peak sales reaching several billion dollars, highlighting obefazimod as a potential new oral option for inflammatory bowel disease.